Imvax creates personalized cancer vaccines by extracting a patient’s resected solid tumor, preserving its full antigen repertoire, and formulating an autologous vaccine that activates both innate and adaptive immunity. This whole‑tumor antigen approach aims to generate a broad, polyclonal immune response capable of targeting residual and metastatic tumor cells across diverse solid‑tumor indications.
Funding
$29M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies often target a limited set of tumor antigens, allowing heterogeneous solid tumors to evade immune detection and leading to modest efficacy in many patients.
Solution
Imvax develops personalized immunotherapies that use the entire antigen repertoire of a patient’s resected solid tumor to prime both innate and adaptive immune responses. The platform extracts tumor tissue, processes it to preserve the full spectrum of tumor-associated antigens, and formulates a vaccine that is administered back to the patient. By presenting the complete antigen signature, the treatment aims to generate a broad, polyclonal immune attack capable of recognizing and eliminating residual and metastatic tumor cells. Early clinical data in glioblastoma demonstrate the approach’s ability to induce measurable immune activity, and the pipeline is expanding to additional solid tumor indications.
Target Audience
Imvax’s therapies target oncologists and cancer treatment centers managing patients with resectable solid tumors, particularly those with high‑grade glioblastoma and other aggressive malignancies.
Features
- Whole‑tumor antigen capture technology that preserves the full diversity of tumor-associated proteins
- Autologous vaccine formulation using patient‑derived tumor material to ensure personalized antigen presentation
- Dual activation of innate immune pathways (e.g., NK cells, macrophages) and adaptive T‑cell responses
- Scalable manufacturing process compatible with surgical tumor resection workflows
- Clinical-grade quality control ensuring sterility, antigen integrity, and batch consistency